Institutional members access full text with Ovid®

Lipid lowering with thyroid hormone and thyromimetics

Angelin, Bo; Rudling, Mats

doi: 10.1097/MOL.0b013e3283402e9c
Therapy and clinical trials: Edited by Anton F. Stalenhoef and John J.P. Kastelein

Purpose of review: To summarize how thyroid hormones exert their effects on lipid metabolism through specific interaction with their nuclear receptors, to review studies of the effects of new and selective thyromimetic drugs in animals and humans and to identify important questions for future research.

Recent findings: Thyroid hormones exert their effects by stimulation of thyroid hormone receptors that have different tissue distribution and metabolic targets. TRβ is predominant in liver and mainly responsible for effects on cholesterol and lipoprotein metabolism, whereas TRα is most important in fat, muscle, and heart. Thyroid hormone analogs (thyromimetics, tiromes) have been developed that activate TRβ and are selectively taken up and/or activated by the liver. Such compounds stimulate hepatic LDL receptors, cholesterol elimination as bile acids and cholesterol, and presumably promote reverse cholesterol transport. In animals, they retard atherosclerosis progression. In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic–pituitary–thyroid feedback. When added to statins, it reduces LDL and non-HDL cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a).

Summary: Liver-specific and β-selective thyroid hormone analogs activate a spectrum of favorable thyroid hormone actions that optimize lipid metabolism and promote cholesterol elimination. Further studies should establish long-term safety and potential clinical usefulness of thyromimetics.

Metabolism Unit, Department of Endocrinology, Metabolism and Diabetes and Molecular Nutrition Unit, Center for Biosciences and Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

Correspondence to Professor Bo Angelin, Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden Tel: +46 8 5858 2344; fax: +46 8 711 0710; e-mail: bo.angelin@ki.se

© 2010 Lippincott Williams & Wilkins, Inc.